Trans-pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci

Neurology: Genetics

Volumn 2, Issue 4, 2016, Pages

  Chan, Gail ^a,c,d   White, Charles C ^a,c,d   Winn, Phoebe A ^a,c   Cimpean, Maria ^a,c   Replogle, Joseph M ^a,c,d   Glick, Laura R ^a,c,d   Cuerdon, Nicole E ^a,c,d   Ryan, Katie J ^a,c,d   Johnson, Keith A ^b,c,d   Schneider, Julie A ^e   Bennett, David A ^e   Chibnik, Lori B ^a,c,d   Sperling, Reisa A ^b,c   De Jager, Philip L ^a,c,d   Bradshaw, Elizabeth M ^a,c,d  

^a Program in Translational NeuroPsychiatric Genomics   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2;

ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DORSOLATERAL PREFRONTAL CORTEX; FEMALE; FLOW CYTOMETRY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MONOCYTE; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSONISM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 85020564730     PISSN: None     EISSN: 23767839     Source Type: Journal    
DOI: 10.1212/NXG.0000000000000090     Document Type: Article

References (33)

1. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-458.
2. Morra LF, Donovick PJ. Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review. Int J Geriatr Psychiatry 2014;29:569-576.
3. Desikan RS, Schork AJ, Wang Y, et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry 2015;20:1588-1595.
4. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neuro-degeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 2013;8:19.
5. Liu G, Liu Y, Jiang Q, et al. Convergent genetic and expression datasets highlight TREM2 in Parkinson's disease susceptibility. Mol Neurobiol Epub 2015 Sep 14.
6. Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis 2013;3:493-514.
7. Theriault P, ElAli A, Rivest S. The dynamics of monocytes and microglia in Alzheimer's disease. Alzheimers Res Ther 2015;7:41.
8. Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 2014;15:300-312.
9. Raj T, Rothamel K, Mostafavi S, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014;344:519-523.
10. De Jager PL, Hacohen N, Mathis D, Regev A, Stranger BE, Benoist C. ImmVar Project: insights and design considerations for future studies of "healthy" immune variation. Semin Immunol 2015;27:51-57.
11. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegenera-tion. Cell 2010;140:918-934.
12. Chan G, White CC, Winn PA, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci 2015;18:1556-1558.
13. Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013;16:848-850.
14. Bennett DA, Shannon KM, Beckett LA, Wilson RS. Dimensionality of Parkinsonian signs in aging and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1999;54:M191-M196.
15. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012;71:258-266.
16. Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005;25:163-175.
17. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res 2012;9:628-645.
18. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush memory and aging project. Curr Alzheimer Res 2012;9:646-663.
19. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014; 46:989-993.
20. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bio-informatics 2012;28:882-883.
21. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinfor-matics 2010;26:2190-2191.
22. Battle A, Khan Z, Wang SH, et al. Impact of regulatory variation from RNA to protein. Science 2015;347:664-667.
23. Williams LM, Ridley AJ. Lipopolysaccharide induces actin reorganization and tyrosine phosphorylation of Pyk2 and Paxillin in monocytes and macrophages. J Immunol 2000; 164:2028-2036.
24. Li X, Hunter D, Morris J, Haskill JS, Earp HS. A calcium-dependent tyrosine kinase splice variant in human monocytes: activation by a two-stage process involving adherence and a subsequent intracellular signal. J Biol Chem 1998;273:9361-9364.
25. Kedzierska K, Vardaxis NJ, Jaworowski A, Crowe SM. FcgR-mediated phagocytosis by human macrophages involves Hck, Syk, and Pyk2 and is augmented by GM-CSF. J Leukoc Biol 2001;70:322-328.
26. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-1458.
27. Patsopoulos NA, Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNb-1b and a CCR1-Antagonist, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011;70:897-912.
28. Lajaunias F, Dayer J-M, Chizzolini C. Constitutive repres-sor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 2005;35:243-251.
29. Hollingworth P, Harold D, Sims R, et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-435.
30. Naj AC, Jun G, Beecham GW, et al. Common variants in MS4A4/MS4A6E, CD2AP, CD33, and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43:436-441.
31. Malik M, Chiles J, Xi HS, et al. Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. Hum Mol Genet 2015;24:3557-3570.
32. Raj T, Ryan KJ, Replogle JM, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet 2014;23:2729-2736.
33. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013;78:631-643.